Corcept Therapeutics Incorporated annual gross profit for fiscal TTM was $817 million, an increase of 9.2% from $748 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $817M | $748M | $664M | $476M | $396M | $361M | $348M | $301M | $246M | $156M | $79M | $49M | $26M | $10M | $3M | $0M | — | $0M | $0M | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Gross Profit | $252M | $162M | $200M | $203M | $191M | $155M | $179M | $180M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More CORT metrics: Revenue · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All CORT financial statements → Interactive CORT charts →
About TickerBase · Data methodology & sources · Privacy · Terms